Cargando…
Should statins be considered for the management of mucormycosis in COVID-19?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Diabetes India. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178941/ https://www.ncbi.nlm.nih.gov/pubmed/34186353 http://dx.doi.org/10.1016/j.dsx.2021.05.035 |
| _version_ | 1783703676903227392 |
|---|---|
| author | Chatterjee, Subhankar Vardhan, Bhagya Singh, Deepa Kumari Maitra, Abhishek Ojha, Umesh Kumar |
| author_facet | Chatterjee, Subhankar Vardhan, Bhagya Singh, Deepa Kumari Maitra, Abhishek Ojha, Umesh Kumar |
| author_sort | Chatterjee, Subhankar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8178941 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Diabetes India. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81789412021-06-05 Should statins be considered for the management of mucormycosis in COVID-19? Chatterjee, Subhankar Vardhan, Bhagya Singh, Deepa Kumari Maitra, Abhishek Ojha, Umesh Kumar Diabetes Metab Syndr Letters to the Editor Diabetes India. Published by Elsevier Ltd. 2021 2021-06-05 /pmc/articles/PMC8178941/ /pubmed/34186353 http://dx.doi.org/10.1016/j.dsx.2021.05.035 Text en © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letters to the Editor Chatterjee, Subhankar Vardhan, Bhagya Singh, Deepa Kumari Maitra, Abhishek Ojha, Umesh Kumar Should statins be considered for the management of mucormycosis in COVID-19? |
| title | Should statins be considered for the management of mucormycosis in COVID-19? |
| title_full | Should statins be considered for the management of mucormycosis in COVID-19? |
| title_fullStr | Should statins be considered for the management of mucormycosis in COVID-19? |
| title_full_unstemmed | Should statins be considered for the management of mucormycosis in COVID-19? |
| title_short | Should statins be considered for the management of mucormycosis in COVID-19? |
| title_sort | should statins be considered for the management of mucormycosis in covid-19? |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178941/ https://www.ncbi.nlm.nih.gov/pubmed/34186353 http://dx.doi.org/10.1016/j.dsx.2021.05.035 |
| work_keys_str_mv | AT chatterjeesubhankar shouldstatinsbeconsideredforthemanagementofmucormycosisincovid19 AT vardhanbhagya shouldstatinsbeconsideredforthemanagementofmucormycosisincovid19 AT singhdeepakumari shouldstatinsbeconsideredforthemanagementofmucormycosisincovid19 AT maitraabhishek shouldstatinsbeconsideredforthemanagementofmucormycosisincovid19 AT ojhaumeshkumar shouldstatinsbeconsideredforthemanagementofmucormycosisincovid19 |